Tomasz RL

Language: Spanish
References: 7
Page: 158-161
PDF size: 73.58 Kb.

ABSTRACT

Objectives: The assessment of therapeutic effects of paroxetyne in major depression syndrome using the psychological scales and patients’ psychiatric treatment. Methods: The group chosen consisted of 99 patients with major depression syndrome. The control group consisted of 98 patients treated with sulpiride. All patients were carefully diagnosed according to 24 points Hamilton Depression Evaluation Scale, Beck Depression Self-Assessment Inventory and Montgomery-Asberg Scale. The effects of the treatment were assessed using the those scales and patients’ psychiatric treatment. Results: Good effects were observed in approximately 80% of all patients. Average results after treatment decreased from 46.2 points to 17.4 points in Hamilton Scale. After treatment with Paroxetine 47.47% patients noted full and fixed remission of the major depression syndrome, 6.06% of patients noted significant improvement, 20.20% noted medium improvement and 6.06% noted only poor improvement. Based on Montgomery-Asberg Scale approximately 47% patients noted full and fixed remission 6% of patients noted significant improvement, 20% noted medium improvement and 6% noted only poor improvement in major depression disease.

REFERENCES

1. Farmacología de los inhibidores selectivos de la recaptación de la serotonina (SSRIs). Pharmacology of selective serotonin reuptake inhibitors (SSRIs). [Aut] El¿bieta Czarnecka, Jaroslaw Strzelec. Farm. Pol. 2001; 57(13): 603-612, il., bibliogr. 46 ítem, sum.

2. Ridout F, Meadows R, Johnsen S, Hindmarch I. Evaluación de efectos de paroxetina y mitrazapina controlada con placebo en los resultados de estudios ligados a la habilidad para conducir máquinas (A placebo controlled investigation into the effects of paroxetine and mitrazapine on measures related to car driving performance). Human Psychopharmacology 2003; 18(4): 261-9.

3. Serretti A, Zanardi R, Cusin C, Rossini D. Gen de hidroxilasa de triptófano asociado a la actividad antidepresiva de la paroxetina (Tryptophan hydroxylase gene associated with paroxetine antidepressant activity). European Neuropsychopharmacology 2001; 11(5):375-80.

4. Sargent PA, Williamson DJ, Cowen PJ. Neurotransmisión cerebral de 5-HT durante el tratamiento con Paroxetina (Brain 5-HT neurotransmission during paroxetine treatment). British Journal of Psychiatry 1998; 172: 49-52.

5. Keller MB. El tratamiento de depresión mayor con paroxetina (Paroxetine treatment of major depressive disorder). Psychopharmacology Bulletin. 37 Suppl. 2003; 1: 42-52, Spring.

6. Szegedi A, Muller MJ, Anghelescu I. Una mejoría temprana como consecuencia del uso de mitrazapina y paroxetina predice con gran exactitud una posterior respuesta estable y remisión en pacientes con depresión mayor (Early improvement under mitrazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression). Journal of Clinical Psychiatry 2003; 64(4): 413-20.

7. Braconnier A, Le Coent R, Cohen D. Paroxetina versus clomipramina en adolescentes con depresión mayor: estudios randomizados multicéntricos dobles ciegos (Paroxetine versus clomipramine in adolescents with severe major depression: a double-blind randomized, multicenter trial). Journal of the American Academy of Child and Adolescent Psychiatry 2003; 42(1): 22-9.